NCT05686642

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	LT3001 Drug:high dose	Administered by intravenous infusion.
DRUG	Placebo	Administered by intravenous infusion.
DRUG	LT3001 Drug:low dose	Administered by intravenous infusion.

Timeline

• Start date: 2023-04-06
• Primary completion: 2025-12-10
• Completion: 2025-12-12
• First posted: 2023-01-17
• Last updated: 2025-04-11

Locations

28 sites across 1 country: China